Uveitis Treatment Market Report 2026

The uveitis treatment market size has grown strongly in recent years. It will grow from $1.53 billion in 2025 to $1.64 billion in 2026 at a compound annual growth rate (CAGR) of 7.5%. The growth in the historic period can be attributed to improved diagnostic awareness of ocular inflammatory diseases, increased use of corticosteroid-based therapies, expansion of ophthalmology specialty clinics, rising incidence of autoimmune disorders, availability of established anti-inflammatory drugs.

The uveitis treatment market size is expected to see strong growth in the next few years. It will grow to $2.19 billion in 2030 at a compound annual growth rate (CAGR) of 7.4%. The growth in the forecast period can be attributed to growing development of monoclonal antibodies for uveitis, increasing focus on steroid-sparing treatment options, expansion of personalized medicine approaches, rising investment in ophthalmic drug pipelines, increasing demand for long-term disease management solutions. Major trends in the forecast period include increasing adoption of biologic therapies, rising use of targeted immunosuppressive treatments, growing focus on personalized uveitis management, expansion of sustained-release ocular drug delivery, increasing clinical research in autoimmune eye disorders.

The rising incidence of autoimmune conditions is expected to drive the growth of the uveitis treatment market in the coming years. Autoimmune conditions are a group of diseases in which the immune system attacks and damages the body’s healthy cells, tissues, or organs. Factors such as genetic predisposition, environmental triggers, and changes in lifestyle and immune system behavior contribute to the increasing prevalence of these conditions. Uveitis treatments help manage autoimmune diseases by reducing inflammation, suppressing overactive immune responses, and preventing vision loss associated with autoimmune-related eye inflammation. For example, in November 2023, the Multiple Sclerosis International Federation (MSIF), a UK-based nonprofit organization focused on global MS research and advocacy, reported that approximately 2.9 million people worldwide were living with multiple sclerosis, a type of autoimmune disease, in 2023. Therefore, the growing prevalence of autoimmune conditions is driving the uveitis treatment market.

Leading companies in the uveitis treatment market are adopting advanced drug-delivery technologies, such as sustained-release intravitreal implants, to provide long-term inflammation control, improve patient adherence, and reduce systemic side effects. Sustained-release intravitreal implants are small, non-bioerodible devices injected into the vitreous cavity of the eye that continuously release corticosteroids over months or years, allowing targeted local therapy, reducing the need for frequent injections, and enhancing patient convenience. For example, in March 2025, ANI Pharmaceuticals, Inc., a US-based biopharmaceutical company, received FDA approval to expand the use of ILUVIEN, a fluocinolone acetonide intravitreal implant, for chronic non-infectious uveitis affecting the posterior segment of the eye. ILUVIEN delivers fluocinolone at a low daily rate for up to 36 months, providing sustained local corticosteroid therapy, minimizing frequent injections, and improving disease control and patient convenience.

In September 2024, ANI Pharmaceuticals, Inc., a US-based pharmaceutical company, acquired Alimera Sciences for an undisclosed amount. This strategic acquisition is aimed at strengthening ANI’s Rare Disease division while expanding its presence in the ophthalmology sector. Alimera Sciences is a US-based biopharmaceutical company specializing in the development and commercialization of ophthalmic pharmaceuticals, particularly for retinal diseases such as uveitis.

Major companies operating in the uveitis treatment market are Merck & Co. Inc., AbbVie Inc., Novartis AG, Regeneron Pharmaceuticals Inc., Bausch & Lomb Incorporated, Horizon Therapeutics plc, Sun Pharmaceutical Industries Ltd., Cipla Ltd., Santen Pharmaceutical Co. Ltd., Galapagos NV, EyePoint Pharmaceuticals Inc., ANI Pharmaceuticals Inc., Clearside Biomedical Inc., Roche Holding AG, Pfizer Inc., Alimera Sciences Inc., Tarsier Pharma Ltd., Oculis Pharma, Priovant Therapeutics, Acelyrin Inc., Eyevensys, Aerie Pharmaceuticals Inc., Aldeyra Therapeutics Inc.

North America was the largest region in the uveitis treatment market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the uveitis treatment market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the uveitis treatment market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Tariffs are impacting the uveitis treatment market by increasing costs of imported active pharmaceutical ingredients, biologics, drug delivery devices, and specialized manufacturing inputs used in corticosteroids, immunosuppressants, and monoclonal antibody therapies. North America and Europe are most affected due to dependence on cross-border pharmaceutical supply chains, while Asia-Pacific faces cost pressures on formulation and packaging imports. These tariffs are contributing to higher treatment costs and pricing pressures for healthcare providers. However, they are also encouraging localized drug manufacturing, regional sourcing of pharmaceutical inputs, and increased investment in domestic ophthalmic drug production capabilities.

The uveitis treatment market research report is one of a series of new reports that provides uveitis treatment market statistics, including uveitis treatment industry global market size, regional shares, competitors with a uveitis treatment market share, detailed uveitis treatment market segments, market trends and opportunities, and any further data you may need to thrive in the uveitis treatment industry. This uveitis treatment market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Uveitis treatment refers to medical interventions designed to reduce inflammation within the eye, relieve symptoms, and prevent vision loss. Depending on the underlying cause, treatments may include corticosteroids, immunosuppressive drugs, or antimicrobial medications. These therapies can be administered as eye drops, oral medications, injections, or implants, tailored to the type and severity of uveitis.

The main indications for uveitis treatment are anterior uveitis, intermediate uveitis, posterior uveitis, and panuveitis. Anterior uveitis involves inflammation of the front part of the uvea, primarily affecting the iris and ciliary body, often causing eye pain, redness, and changes in vision. Uveitis treatments can be classified by route of administration into topical, systemic, and injectable therapies, targeting either infectious or non-infectious causes. Therapeutic options include corticosteroids, immunosuppressants, monoclonal antibodies, cycloplegic agents, antibiotics, antivirals, antifungals, and analgesics, distributed through hospital pharmacies, retail pharmacies, online pharmacies, and other channels.

The uveitis treatment market consists of sales of drugs, diagnostic tools, surgical equipment, intravitreal implants, and injections. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.